Cumberland Pharmaceuticals Inc. — Q1 2014 Form 10-Q Summary
Business context and reporting period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing branded prescription products, primarily in hospital acute care and gastroenterology. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Net revenues | $8.1 million | $10.3 million | Down 21.1% |
| Operating income | $0.4 million | $1.3 million | Down 69.2% |
| Net income attributable to common shareholders | $0.3 million | $0.9 million | Down 66.5% |
| Diluted EPS | $0.02 | $0.05 | Decreased |
| Cash flow from operations | $1.0 million | $1.7 million | Down 41.2% |
- Gross margin was approximately 87.0%, compared with 89.2% in the prior-year quarter, reflecting an unfavorable product mix.
- Operating margin was approximately 5.0%, compared with 12.9%; net income margin attributable to common shareholders was approximately 3.5%, compared with 8.3%.
- Cash and cash equivalents were $39.0 million at March 31, 2014, compared with $40.9 million at December 31, 2013. Marketable securities totaled $13.5 million, producing total cash, cash equivalents and marketable securities of $52.6 million.
- Working capital was $57.9 million, and the current ratio was 6.1x, versus $61.1 million and 9.1x at year-end 2013.
- The company had no borrowings under its revolving credit facility. The facility provided $10.0 million of availability, with an interest rate of LIBOR plus an applicable margin of 2.15% at March 31, 2014. The facility expires December 31, 2014, subject to amendments and conditions.
- Total assets were $91.1 million and total liabilities were $12.1 million at March 31, 2014.
Material changes versus the prior comparable period
- Revenue declined primarily because Acetadote revenue fell by approximately $4.5 million, reflecting lower branded sales and increasing generic competition. Authorized generic Acetadote revenue was $1.3 million, compared with $3.0 million in Q1 2013.
- Kristalose revenue increased 59.5% to approximately $3.4 million, supported by repositioning, a price increase and patient affordability initiatives.
- New products generated $1.1 million of Omeclamox-Pak revenue and $0.3 million of Vaprisol revenue.
- Research and development expense declined 43.0% to $0.8 million following the completion of certain Caldolor clinical studies.
- General and administrative expense declined to $1.9 million from $2.6 million, primarily due to lower salary and consulting costs and lower inventory donations.
- Amortization increased to $0.3 million from $0.1 million, primarily due to increased capitalized patents and patent defense costs.
- Cash used in investing activities was $2.1 million, including the $2.0 million Vaprisol acquisition. Cash used in financing activities was $0.7 million, including $0.9 million of share repurchases.
- The company repurchased 193,486 shares for approximately $0.9 million during the quarter, leaving approximately $4.7 million available under the repurchase authorization at March 31, 2014.
Guidance, outlook, commentary and risks
- Management expects internally generated cash flows and available credit to be adequate to service existing obligations, finance internal growth and fund capital expenditures; no formal revenue or earnings guidance was provided.
- The company launched Omeclamox-Pak distribution and promotion efforts in early 2014 and relaunched active promotion of Vaprisol in early May 2014. Vaprisol is intended to leverage the existing hospital sales organization.
- Management expects to pay minimal income taxes in 2014 because of approximately $43.2 million of unrecognized net operating loss carryforwards related to nonqualified stock option exercises.
- In April 2014, the company initiated arbitration against Mylan, alleging breaches of agreements requiring exclusive manufacture and supply of acetylcysteine products through April 2016. The company seeks monetary damages or injunctive relief; the outcome is uncertain.
- Acetadote patents are being challenged on invalidity and non-infringement grounds. Loss of patent protection could lead to increased competition, lower sales and adverse financial results.
- Inventory totaled $7.4 million, primarily Caldolor. Cumulative reserves for potential obsolescence and discontinuance losses were approximately $3.4 million; additional charges could result if sales are below projections.
- Vaprisol includes a potential milestone payment of up to $2.0 million based on first-year sales, and Omeclamox-Pak includes up to $4.0 million of additional anniversary milestones.
- Management identified product sales, generic competition, product acquisitions, acquisition integration, access to capital, regulatory matters, intellectual property litigation and inventory obsolescence as significant risks.
Important facts for investors to verify
- Whether the decline in Acetadote sales and generic competition continues and how it affects revenue concentration and margins.
- Actual adoption, profitability and milestone obligations associated with Omeclamox-Pak and Vaprisol.
- The status and potential financial impact of the Mylan arbitration and Acetadote patent challenges.
- Whether Caldolor inventory can be sold before expiration and whether additional obsolescence reserves are required.
- The December 31, 2014 expiration and covenant requirements of the revolving credit facility.
- The company’s ability to sustain operating cash generation while funding acquisitions, clinical studies, commercialization and share repurchases.